Introduction Acute Liver Failure caused by Hepatitis A remains an important cause of mortality in young adults in developing countries. Although Therapeutic Plasma Exchange has shown benefit in acute liver failure overall, disease-specific evidence in hepatitis A virus-related ALF has been lacking.
Introduction
Acute Liver Failure caused by Hepatitis A remains an important cause of mortality in young adults in developing countries. Although Therapeutic Plasma Exchange has shown benefit in acute liver failure overall, disease-specific evidence in hepatitis A virus-related ALF has been lacking.
Problem Statement
The role of plasma exchange in HAV-related acute liver failure remains uncertain, particularly regarding patient selection and hemodynamic status. Existing data are limited, and it is unclear whether all patients benefit equally from extracorporeal support strategies.
Summary
This large Indian multicenter cohort study evaluated the real-world effectiveness of plasma exchange compared with standard medical treatment in patients with hepatitis A-related acute liver failure across 13 tertiary centers.
The study included more than 230 patients, making it one of the largest HAV-ALF cohorts evaluating plasma exchange to date.
Overall in-hospital native liver survival did not significantly differ between patients treated with plasma exchange and those receiving standard medical therapy alone. This finding suggests that routine universal application of plasma exchange in all HAV-ALF patients may not improve outcomes.
However, an important signal emerged in a clinically relevant subgroup. Among hemodynamically stable patients not requiring inotropes, survival appeared substantially better in the plasma exchange cohort on univariate analysis.
This observation is biologically plausible because patients without advanced circulatory collapse may better tolerate extracorporeal therapy and may still possess reversible hepatic injury amenable to supportive immune and toxin-modulating interventions.
Nevertheless, the survival advantage was not maintained after propensity score matching and regression adjustment, indicating potential selection bias and residual confounding within this retrospective dataset.
The findings therefore suggest that hemodynamic stability may be an important determinant of response to plasma exchange rather than plasma exchange being universally beneficial across all HAV-ALF phenotypes.
Clinically, the study highlights the heterogeneity of acute liver failure and reinforces the need for individualized extracorporeal support strategies rather than protocolized blanket therapy.
The work is particularly relevant in the Indian setting, where hepatitis A continues to contribute significantly to acute liver failure burden and transplant access remains limited.
Importantly, the cohort also included patients fulfilling King's College Criteria, reflecting inclusion of severe disease presentations encountered in real-world hepatology practice.
The study further raises important questions regarding optimal timing, patient selection and intensity of plasma exchange in viral acute liver failure.
Potential mechanisms of benefit may include reduction of inflammatory mediators, removal of circulating toxins, correction of coagulopathy and temporary support of systemic homeostasis during hepatic recovery.
However, advanced multiorgan dysfunction and vasoplegia may limit the efficacy of extracorporeal support once systemic decompensation becomes established.
The retrospective design, inter-center variability and non-randomized treatment allocation remain important limitations. Additionally, differences in disease severity and referral patterns may have influenced treatment selection.
Future prospective randomized studies focused specifically on hemodynamically stable HAV-ALF populations are needed to clarify whether an early “window of opportunity” exists where plasma exchange can alter native liver survival.
The findings also support development of more refined prognostic models integrating hemodynamic status, inflammatory biomarkers and dynamic organ failure assessment to guide extracorporeal therapy decisions.
Overall, this multicenter Indian study suggests that plasma exchange does not improve survival across all patients with hepatitis A-related acute liver failure, but it may offer benefit in carefully selected hemodynamically stable patients who are not yet requiring inotropic support.
Introduction: IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder that can affect virtually any organ. Although glucocorticoids remain the mainstay of treatment, relapse is common after tapering, and long-term steroid toxicity remains a major concern....
Introduction: Hepatitis B virus (HBV) reactivation remains a potentially serious complication of immunosuppressive and anticancer therapies. While current guidelines classify patients into high-, moderate-, and low-risk categories, this editorial discusses new real-world evidence suggesting that...
Introduction: Liver disease is entering a new era. While steatotic liver disease (SLD) is rapidly becoming one of the world's leading non-communicable diseases, progress toward viral hepatitis elimination has slowed. This editorial highlights the urgent...
Introduction: Therapeutic plasma exchange (TPE) is increasingly used in pediatric acute liver failure (ALF), but it artificially lowers bilirubin and INR, making it difficult to determine whether a child is truly improving or requires urgent...
Introduction: For decades, low-to-moderate alcohol consumption has been considered by some to offer potential cardiovascular benefits. This comprehensive U.S. modeling study re-evaluated the lifetime health impact of alcohol consumption using contemporary cause-specific data on alcohol-related...
Introduction: Advances in genetic sequencing have transformed the understanding of cholestatic liver diseases. Conditions once considered exclusive to children are now recognized in adolescents and adults, with genetic variants increasingly explaining unexplained cholestasis, recurrent pruritus,...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.